After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, RARE falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Ultragenyx Pharmaceutical Inc. is $5.08B. A total of 0.81 million shares were traded on the day, compared to an average of 705.63K shares.
In the most recent transaction, Horn Howard sold 7,465 shares of RARE for 52.76 per share on Oct 10 ’24. After the transaction, the Chief Financial Officer now owns 92,301 company shares. In a previous transaction on Sep 03 ’24, KAKKIS EMIL D sold 20,000 shares at 55.85 per share. RARE shares that President & CEO owns now total 2,223,985.
Among the insiders who sold shares, Huizenga Theodore Alan disposed of 91 shares on Sep 03 ’24 at a per-share price of $56.19. This resulted in the SVP, Chief Accounting Officer holding 41,551 shares of RARE after the transaction. In another insider transaction, KAKKIS EMIL D bought 20,000 shares at $55.85 per share on Sep 03 ’24.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, RARE has a high of $60.37 and a low of $31.52.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. RARE’s latest balance sheet shows that the firm has $740.20M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $4.70, while its Total Shareholder’s Equity was $922.56M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RARE is Buy with a score of 4.86.
